Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab
- Sponsor
- Spanish Lung Cancer Group
- Study ID
- NCT01814163
- Status
- Completed
Conditions
- Nonsquamous Nonsmall Cell Neoplasm of Lung
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- paclitaxel, carboplatin and bevacizumab — DRUGPaclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
Study Details
This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line therapy in patients with non-squamous advanced non-small cell lung cancer.
Key Dates
- First listed
- Mar 19, 2013
- Start date
- Feb 28, 2011
- Status verified
- Mar 2013
- Primary completion
- Feb 28, 2013
- Completion
- Feb 28, 2013
Study Design
- Enrollment
- 200 participants (actual)
Arms
- Arm: Paclitaxel, carboplatin and bevacizumabPaclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
Primary Outcome Measure
Correlation between angiogenesis markers and progression free survival. [ Time Frame: 1 year ]